What medication should be used to treat chronic folliculitis in an HIV‑positive patient?

Treatment of Chronic Folliculitis in HIV-Positive Patients

For chronic folliculitis in HIV-positive patients, initiate itraconazole 200–400 mg/day as first-line therapy, with UVB phototherapy as the gold standard if itraconazole fails; optimize antiretroviral therapy concurrently, as immune reconstitution with CD4 counts >250 cells/µL often leads to spontaneous resolution.

Diagnostic Clarification and Pathophysiology

The term "chronic folliculitis" in HIV encompasses two distinct entities that require different management approaches:

• HIV-associated eosinophilic folliculitis (HIV-EF) is a culture-negative, intensely pruritic follicular eruption occurring in patients with CD4 counts <250–300 cells/µL, characterized histologically by follicular infiltration with eosinophils and peripheral eosinophilia in 77% of cases. 1

• Immune recovery folliculitis (IRF) develops paradoxically after ART initiation or switch, driven by rapid CD8+ T-cell reconstitution and immune response against skin commensals (Demodex folliculorum, Cutibacterium acnes). 2

• HIV-EF serves as a clinical marker of advanced immunosuppression and increased risk for opportunistic infections, making concurrent evaluation of CD4 count and ART status mandatory. 1

First-Line Systemic Therapy: Itraconazole

Itraconazole 200 mg/day initially, escalating to 300–400 mg/day if needed, is the preferred systemic agent for HIV-associated eosinophilic folliculitis. 3

• High-dose itraconazole (300–400 mg/day) achieves cure in a subset of patients, suggesting fungal pathogens (Malassezia species) contribute to pathogenesis in some cases. 4

• Treatment duration should extend until complete clinical resolution, typically requiring several weeks of therapy. 3

• Monitor liver function tests periodically when treatment exceeds 21 days, as prolonged azole therapy carries hepatotoxicity risk. 5

Alternative Systemic Options When Itraconazole Fails or Is Contraindicated

Isotretinoin (Highly Effective)

• Isotretinoin 1 mg/kg/day produces complete symptomatologic and clinical remission within 1–4 weeks in 100% of patients with HIV-EF. 6

• After a single course, 57% of patients remain in complete remission for up to 9 months; the remaining 43% experience brief relapses that respond rapidly to repeat courses. 6

• Isotretinoin represents a promising treatment option warranting consideration when itraconazole is ineffective or poorly tolerated. 3, 6

Antihistamines (Cetirizine)

• Cetirizine 20–40 mg/day exploits specific anti-eosinophilic properties and has demonstrated efficacy in case reports. 3, 7

• This option is particularly useful when systemic antifungals and retinoids are contraindicated or when pruritus is the dominant symptom. 3

Metronidazole

• Metronidazole 250 mg three times daily is an alternative systemic option, though evidence is limited to case series. 3

Gold Standard: UVB Phototherapy

UVB phototherapy is the gold standard treatment for HIV-associated eosinophilic folliculitis and is often curative when topical corticosteroids, indomethacin, and systemic agents fail. 3, 1

• UVB should be considered the definitive therapy for refractory cases unresponsive to itraconazole, isotretinoin, or antihistamines. 3

• PUVA (psoralen + UVA) photochemotherapy is an alternative phototherapy modality with some efficacy but less favorable risk-benefit profile than UVB. 3

Topical Therapy (Adjunctive or Mild Disease)

• Topical corticosteroids (e.g., clobetasol propionate) are first-line for localized or mild disease and produce clinical response in HIV-EF. 3, 1

• Topical tacrolimus is useful as initial therapy for mild cases or as adjunctive treatment. 3

• Topical permethrin may be considered when Demodex infestation is suspected, particularly in immune recovery folliculitis. 3

Less Preferred Options with Uncertain Risk-Benefit Ratios

• Oral indomethacin 50–75 mg/day is effective for classic (non-HIV) eosinophilic pustular folliculitis but carries significant risk of peptic ulceration, limiting its use in HIV patients. 3

• Oral corticosteroids, cyclosporine 5 mg/kg/day, interferon-alpha-2b, and interferon-gamma have shown some efficacy but carry substantial toxicity concerns in immunocompromised patients. 3

• Minocycline 100 mg twice daily and dapsone 50–100 mg twice daily have been used with modest effect but are not first-line agents. 3

The Paramount Role of Antiretroviral Therapy

Initiation or optimization of highly active antiretroviral therapy (HAART) is the most effective long-term strategy for HIV-associated eosinophilic folliculitis and often leads to spontaneous amelioration as CD4 counts rise above 250 cells/µL. 3, 8

• Effective ART reduces the frequency and severity of HIV-EF more than any antifungal or immunomodulatory agent. 3

• For ART-naïve patients, preferred first-line regimens include tenofovir (TDF or TAF) + lamivudine or emtricitabine (XTC) combined with dolutegravir, bictegravir, or doravirine; dual therapy with XTC + dolutegravir is also acceptable. 8

• In immune recovery folliculitis occurring after ART initiation or switch, the eruption typically resolves spontaneously within weeks to months as immune homeostasis is achieved; symptomatic management with topical corticosteroids or benzoyl peroxide may suffice. 2

Treatment Algorithm

1. Confirm diagnosis via skin biopsy showing follicular eosinophilic infiltrate and rule out bacterial folliculitis with negative bacterial cultures. 1

2. Assess CD4 count and ART status: HIV-EF occurs with CD4 <250–300 cells/µL; IRF occurs after ART initiation/switch. 1, 2

3. Initiate or optimize ART immediately, as immune reconstitution is the definitive long-term solution. 3, 8

4. For mild localized disease: Start topical corticosteroids (clobetasol propionate) or topical tacrolimus. 3, 1

5. For moderate-to-severe or refractory disease: Initiate itraconazole 200 mg/day, escalating to 300–400 mg/day if no response after 2–4 weeks. 3, 4

6. If itraconazole fails or is contraindicated: Switch to isotretinoin 1 mg/kg/day or cetirizine 20–40 mg/day. 3, 6, 7

7. If all systemic agents fail: Proceed to UVB phototherapy, which is often curative. 3, 1

8. Monitor for immune recovery folliculitis in patients starting or switching ART; manage symptomatically with topical agents, as spontaneous resolution is expected. 2

Critical Pitfalls to Avoid

• Do not treat empirically with antibiotics for culture-negative folliculitis in HIV patients with CD4 <250 cells/µL; this represents HIV-EF, not bacterial folliculitis, and antibiotics will fail. 1

• Do not delay ART initiation or optimization while pursuing antifungal or immunomodulatory therapy; immune reconstitution is the most important intervention. 3, 8

• Do not confuse immune recovery folliculitis with drug hypersensitivity; IRF occurs within weeks of ART initiation/switch and is self-limited, whereas drug reactions typically require ART modification. 2

• Do not use oral indomethacin as first-line therapy in HIV patients due to high risk of peptic ulceration in this population. 3

• Do not overlook the diagnosis by misattributing the eruption to acne vulgaris, rosacea, bacterial folliculitis, or seborrheic dermatitis—all common misdiagnoses of HIV-EF. 9